专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230127347A1 ANTIBODIES 有权
公开(公告)号：US20230127347A1
公开(公告)日：2023-04-27
申请号：US17913457
申请日：2021-04-01
申请人： Oxford University Innovation Limited
发明人： Rebecca POWELL DOHERTY , Nicola TERNETTE , Jack SATSANGI
IPC分类号： C07K16/24 , A61P37/00
摘要： Provided is an anti-TNF-α antibody comprising a sequence modification that inhibits presentation of the antibody by human leukocyte antigen (HLA) molecules. The anti-TNF-α antibody may be infliximab or a fragment or variant thereof. In this case, the modification is suitably one that inhibits presentation of the antibody by DRB1*03:01, such as a modification in the region corresponding to residues 1 to 21 of SEQ ID NO: 1, or a modification in the region corresponding to residues 145 to 159 of SEQ ID NO: 1. Alternatively, the anti-TNF-α antibody may be adalimumab or a fragment or variant thereof. In this case, the modification may be one that inhibits presentation of the antibody by DQA1*05:05/DQB1*03:01. Also provided are nucleic acid sequences that encode an antibody according to the invention, and pharmaceutical composition comprising an antibody or nucleic acid sequence of the invention. The antibodies and pharmaceutical compositions of the invention may be of use in the treatment of autoimmune diseases, or disorders selected from the group consisting of: Crohn's disease; ulcerative colitis; rheumatoid arthritis; psoriatic arthritis; psoriasis; ankylosing spondylitis; and Behçet's disease.

2. 发明申请

US20230122171A1 Use of Brazikumab to Treat Crohn's Disease 有权
公开(公告)号：US20230122171A1
公开(公告)日：2023-04-20
申请号：US17819087
申请日：2022-08-11
申请人： ASTRAZENECA COLLABORATION VENTURES, LLC
发明人： Steven Shiff , Carl Gommoll , Aparna Sahoo
IPC分类号： C07K16/24 , A61P1/00 , G01N33/68
摘要： The disclosure relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23, but do not inhibit IL-12. The disclosure also relates to methods of selecting a subject amenable to IL-23 inhibition therapy to treat Crohn's disease as well as methods of identifying a patient sub-population amenable to such treatment.

3. 发明申请

US20230115331A1 GLYCOTARGETING THERAPEUTICS 有权
公开(公告)号：US20230115331A1
公开(公告)日：2023-04-13
申请号：US17810561
申请日：2022-07-01
申请人： École Polytechnique Fédérale de Lausanne (EPFL)
发明人： Jeffrey A. Hubbell , David Scott Wilson
IPC分类号： A61K47/64 , C07K14/77 , A61K38/20 , A61K39/00 , A61K47/54 , A61K38/38 , A61K38/17 , C07K16/28 , A61K38/08 , A61K39/35 , A61K38/37 , C07K16/24 , A61K38/16 , A61K38/28 , A61K38/00
摘要： Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

4. 发明申请

US20230112863A1 IL-1 Binding Proteins 有权
公开(公告)号：US20230112863A1
公开(公告)日：2023-04-13
申请号：US17733303
申请日：2022-04-29
申请人： AbbVie Inc.
发明人： Chengbin WU , Dominic J. AMBROSI , Chung-ming HSIEH , Tariq GHAYUR
IPC分类号： C07K16/24 , C07K14/545 , A61K47/68 , A61K39/395 , A61K45/06 , G01N33/68 , A61K9/00
摘要： Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.

5. 发明授权

US11618783B2 Anti-FAM19A5 antibodies and uses thereof 有权
公开(公告)号：US11618783B2
公开(公告)日：2023-04-04
申请号：US16626624
申请日：2018-06-27
申请人： Neuracle Science Co., Ltd.
发明人： Bongcheol Kim , Jae-Keun Lee , Dong Sik Kim , Junho Chung , Junyeong Jin
IPC分类号： C07K16/00 , A61K39/395 , C07K16/24 , A61P35/00 , G01N33/50 , G01N33/574 , A61K39/00
摘要： The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.

6. 发明授权

US11613582B2 Anti-IL-6/IL-6R antibodies and methods of use thereof 有权
公开(公告)号：US11613582B2
公开(公告)日：2023-03-28
申请号：US16944828
申请日：2020-07-31
申请人： NovImmune, SA
发明人： Walter Ferlin , Marie Kosco-Vilbois , Greg Elson , Olivier Leger , Florence Guilhot
IPC分类号： C07K16/28 , C07K16/24
摘要： This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

7. 发明申请

US20230085357A1 INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF 有权
公开(公告)号：US20230085357A1
公开(公告)日：2023-03-16
申请号：US17930857
申请日：2022-09-09
申请人： Xeris Pharmaceuticals, Inc.
发明人： Martin DONOVAN , Steven PRESTRELSKI , Scott COLEMAN , Brian SLOAT , Diana BOWMAN , Richard FITCH
IPC分类号： A61K9/06 , A61K47/26 , A61K47/12 , A61K47/44 , C07K16/32 , C07K16/28 , C07K16/24 , A61K38/26 , A61K38/28 , A61K38/46 , A61K38/47 , A61K38/50 , A61K38/48 , A61K38/58 , A61K31/7088 , A61K31/7076 , A61K38/49 , A61K38/35 , A61K38/24 , A61K38/18 , A61K38/23 , A61K31/137 , A61K31/4045 , A61K31/136 , A61K31/337 , A61K31/5513 , A61K9/00 , C07K16/22 , A61K38/44
摘要： The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.

8. 发明申请

US20230084464A1 ANTIBODY WITH BINDING SPECIFICITY FOR HUMAN IL-13 有权
公开(公告)号：US20230084464A1
公开(公告)日：2023-03-16
申请号：US17787039
申请日：2020-12-18
申请人： UCB BIOPHARMA SRL
发明人： Daniel John Lightwood , Ralph Adams , Roger Thomas Palframan
IPC分类号： C07K16/24 , C12N15/63 , A61P17/00
摘要： The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing the antibody molecules.

9. 发明申请

US20230082287A1 METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODY 有权
公开(公告)号：US20230082287A1
公开(公告)日：2023-03-16
申请号：US17759538
申请日：2021-01-28
申请人： Novartis AG
发明人： Ankur AJMERA , Jürgen DEDERICHS , Sarah Schmidt GRANT , Kristin HENSON , Monish JAIN , Sandro PAGANI , Yinuo PANG , Marianna ROWLANDS
IPC分类号： C07K16/24 , A61K9/00 , A61P11/00 , A61K45/06
摘要： The present disclosure relates to methods, treatment regimens, uses, kits, compositions and medicaments for treating an inflammatory or obstructive airway disease, such as asthma, including severe asthma, or COPD, by employing an anti-TSLP antibody or anti-TSLP antibody fragment.

10. 发明申请

US20230078678A1 FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS 有权
公开(公告)号：US20230078678A1
公开(公告)日：2023-03-16
申请号：US17760427
申请日：2021-02-12
申请人： AMGEN INC.
发明人： Alexis Lueras , Christopher Sloey
IPC分类号： C07K16/24 , A61P17/00
摘要： Provided herein are aqueous compositions comprising (a) an anti-TSLP antibody at a concentration greater than about 140 mg/mL, (b) a surfactant, and (c) at least one basic amino acid or a salt thereof. Also provided are aqueous compositions comprising aqueous compositions comprising (a) an anti-TSLP antibody at a concentration greater than about 140 mg/mL, (b) a surfactant, and (c) at least one calcium salt or magnesium salt. Related articles of manufacture, pre-filled syringes, and vials comprising the compositions of the present disclosure are also provided. Uses of the compositions for treating an inflammatory disease, e.g., atopic dermatitis, are provided herein. Also, methods of making a stable, liquid antibody comprising having a viscosity of less than about 100 cP is provided herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式